{"filing":{"accession_number":"0001193125-26-293485","cik":"0000034956","ticker":"TENX","company_name":"TENAX THERAPEUTICS, INC.","form":"8-K","filing_date":"2026-07-02","report_date":null,"primary_document":"d20457d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/34956/000119312526293485/d20457d8k.htm"},"events":[{"id":15690,"run_id":13989,"accession_number":"0001193125-26-293485","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"The disclosure announces a Phase 3 clinical trial presentation at a major medical conference (ESC Congress 2026) and provides an update on the timing of topline data release (August 2026). This is a material operational/clinical milestone for a development-stage pharmaceutical company, as it signals progress toward potential regulatory approval of TNX-103 for PH-HFpEF. While not a specific event type like earnings release or M\u0026A activity, it represents a significant clinical and strategic development that would affect investor assessment of the company's pipeline advancement.","company_name":"TENAX THERAPEUTICS, INC.","ticker":"TENX","filing_date":"2026-07-02","form":"8-K","submitted_at":null,"items":[{"id":13563,"accession_number":"0001193125-26-293485","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces a Phase 3 clinical trial presentation at a major medical conference (ESC Congress 2026) and provides an update on the timing of topline data release (August 2026). This is a material operational/clinical milestone for a development-stage pharmaceutical company, as it signals progress toward potential regulatory approval of TNX-103 for PH-HFpEF. While not a specific event type like earnings release or M\u0026A activity, it represents a significant clinical and strategic development that would affect investor assessment of the company's pipeline advancement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T12:02:10.046280+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":13563,"accession_number":"0001193125-26-293485","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces a Phase 3 clinical trial presentation at a major medical conference (ESC Congress 2026) and provides an update on the timing of topline data release (August 2026). This is a material operational/clinical milestone for a development-stage pharmaceutical company, as it signals progress toward potential regulatory approval of TNX-103 for PH-HFpEF. While not a specific event type like earnings release or M\u0026A activity, it represents a significant clinical and strategic development that would affect investor assessment of the company's pipeline advancement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T12:02:10.046280+00:00","company_name":"TENAX THERAPEUTICS, INC.","ticker":"TENX","filing_date":"2026-07-02"}]}